{"Objective": [106, 255, 0], "Methods": [256, 539, 0, 4420, 8465, 1], "Results": [540, 1332, 0, 8466, 18828, 1], "Conclusion": [1333, 1821, 0], "What is already known about this subject?": [1836, 2083, 0], "What does this study add?": [2084, 2530, 0], "How might this impact on clinical practice or future developments?": [2531, 2859, 0], "Key messages": [1822, 2859, 1], "Introduction": [2860, 4419, 0], "Study participants": [4429, 6057, 0], "Serological testing": [6058, 6632, 0], "T-cell ELISpot": [6633, 7694, 0], "Statistical analysis": [7695, 8253, 0], "Patient involvement": [8254, 8465, 0], "Sample collection and baseline data": [8475, 9647, 0], "Immunological response to first-dose vaccine in infection-na\u00efve patients": [9648, 13021, 0], "Immunological response to second-dose vaccine in infection-na\u00efve patients": [13022, 17746, 0], "Immunological response to vaccination in patients with prior natural infection": [17747, 18828, 0], "Discussion": [18829, 24500, 0]}